恒瑞医药高薪诚聘恒瑞医药（股票代码600276）是一家以生产和销售抗肿瘤药、手术用药、心血管及内分泌药物为主的创新型制药企业，国家定点麻醉药品生产厂家。2000年在沪市上市，2010年在医药上市企业最具竞争力二十强评选中，公司名列第一，股票市值位列A股医药上市企业前三名。公司建有国家级企业技术中心，国家级博士后科研工作站，是国家重点高新技术企业，国家“863”计划成果产业化基地，国家火炬计划新医药研究开发及产业化基地的骨干企业之一。恒瑞医药是国内最大的抗肿瘤药物研究和生产基地，先后打造了艾恒、艾素、艾力等众多知名品牌，市场份额在国内排名第一；此外，公司生产的手术用药、消化道用药所占市场份额居国内行业前列。2008年，国家科技部组织实施“重大新药创制”专项，恒瑞医药以企业第一名的评分率先入选重大专项新药孵化器基地。2010年被科技部评定为“中国抗肿瘤药物技术创新产学研联盟”的牵头单位。2010年被国家工信部评为国内最佳研发产品线十佳第一名。2009年8月，公司自主研发的用于治疗Ⅱ糖尿病的一类新药瑞格列汀在美国获批进入一期临床，这是我国化学制药行业首次在美国进行创新药的临床试验，下一步公司还将向美国申请抗肿瘤创新药进行临床实验。恒心致远，瑞颐人生。恒瑞人一直秉承“为人类创造健康生活”的理念，为铸就百年恒瑞而不断努力奋斗。恒瑞医药在美国、上海和连云港、成都均设立研究中心，并在北京设立临床医学部，拥有各类高层次研发人员700多名，其中有400名博士、硕士及海归人士。Jiangsu Hengrui Medicine is a fully integrated pharmaceutical company with R & D, manufacturing, and sales of oncology, CV, anti-infective, surgical drugs and contrast media.State Designated Manufacturer of Narcotic Drugs .Hengrui Medicine has Listed in Shanghai Securities Exchange in 2000; In 2010, ranked first among 20 of the most competitive public companies in the pharma sector in China; Ranked as top three in the stock market value of A Gu of Chinese public pharmaceutical companies.Designated head liaison by Ministry of Chinese Science and Technology for the China Research Alliance of Innovation in Anti-neoplastic Drugs.Hengrui Medicine has two state-of-art R&D centers in Shanghai and Lianyungang. Its medical department is located in Shanghai. In addition, there are four oversee R&D facilities in US and Sweden. Currently over 600 scientists are employed, including 150 PhD, MS, and oversee returnees. Retgliptin, a DPP-4 inhibitor, was tested in Phase 1 in the US in August, 2009. This was the first entry of an NME created by a Chinese pharmaceutical company in the US for clinical evaluation. A series of NMEs in the area of oncology& diabetes are being prepared for clinicaltests on a global scale.A fully integrated, globally-competitive pharmaceutical company capable of delivering 1-2 NMEs annually to patients with unmet medical needs.